Parmax Pharma Ltd. Stock Analysis 540359.BO

Parmax Pharma Ltd. engages in the manufacture of bulk drugs like ampicilin, amoxycillin, cephalexin, and nalidixic acid. The company is headquartered in Rajkot, Gujarat and currently employs 82 full-time employees. The company went IPO on 2017-03-16. The company uses quality by design techniques to produce complex molecules enabling customers to create formulations. The Company’s manufacturing units run in accordance with current good manufacturing practices (cGMP). Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Ormeloxifene Hydrochloride I.P., Milnacipram HCl, Calciumpoly Carbophil usp, Levosulpride, Paliperidone, Edaravone, Lacosamide, Iloperidone, Prasugrel HCl, 2-Acetyl Thiophene, Morpholine Hydrochloride, Camphor Sulfonyl Chloride, ISB-I (2-Chlorobenzaldehyde-5-Sulfonic acid disodium salt), Benzaldehyde-2, 5-Di-Sulfonic acid disodium salt, 2-picolinoxylidide, 4-Octyl amino pyridine (4-OAP), Sitagliptin phosphate Monohydrate API, Solifenacin Succinate API, Vilazodone Hydrochloride API, and Azelnidipine API.